Read by QxMD icon Read


Z Vujicic
No abstract text is available yet for this article.
November 2015: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
Jyun Horiguchi
Yi-gan san (YGS, yokukan-san in Japanese) was developed in 1555 by Xue Kai as a remedy for restlessness and agitation in children. Prompted by the increasing life expectancy of the Japanese population, geriatricians have begun to use this traditional regimen for behavioral and psychological symptoms of dementia in the elderly. Moreover, we reported that YGS therapy is a well-tolerated and effective remedy that improves the symptoms of schizophrenia., borderline personality disorder, Charles Bonnet Syndrome, pervasive developmental disorder...
2012: Seishin Shinkeigaku Zasshi, Psychiatria et Neurologia Japonica
V Aghababian, P Auquier, K Baumstarck-Barrau, C Lançon
BACKGROUND: Shizophrenia is a long-lasting condition with either episodic or continuous evolution that can result in physical, psychological, and social problems related to both the disease itself and the potential side-effects of treatments. These various aspects should be taken into account when assessing the outcome of medical management of patients suffering from schizophrenia. Subjective criteria, such as quality of life (QoL) measurements, should be considered an important focus for evaluation in this population...
June 2011: L'Encéphale
N Takei, P Sham, E Callaghan, G Glover, R Murray
First admission psychiatric patients born in England and Wales between 1938 and 1963, and discharged from hospitals in England and Wales between 1976 and 1986, were examined. Using logistic regression, we tested the hypothesis that the risk of shizophrenia varies by place, and season of birth. Persons born in city areas showed a 12% greater risk of schizophrenia (odds ratio 1.12; 95% confidence interval 1.06 to 1.19) than those born in non-city areas, when compared with other psychiatric patients. The increase in risk was particularly high for individuals born in city areas in winter (21%, ie odds ratio 1...
1995: European Psychiatry: the Journal of the Association of European Psychiatrists
No abstract text is available yet for this article.
August 1949: Journal of Consulting Psychology
Piotr Tomczak
AIMS: (1) The correlations between: (1.1) various aspects of religiousness and (1.2) age, anxiety-state, anxiety-trait, locus of control, and, in the group of patients with shizophrenia: span of treatment, rate of therapy, ego psychopathology, paranoid and depression dimensions, self-rating of state of self-feeling, state of feeling of illness, and quality of life and (2) the comparison of various aspects of religiousness of patients with schizophrenia and healthy people were studied...
September 2006: Psychiatria Polska
L Rofes, A Bueno, J Valero, A Labad
INTRODUCTION: There are some non-psychotic symptoms that can forecast the onset of psychosis. Discovering the differences between the symptoms that lead to disease and those that do not makes it possible to identify them and permits early treatment of the disease. METHODS: A sample of 689 schizophrenic patients was analyzed retrospectively. This sample was obtained from the clinical records database of the University Psychiatric Hospital Institut Pere Mata. Data were analyzed with the SPSS version 9...
January 2003: Actas Españolas de Psiquiatría
J J Miguel-Hidalgo
SmithKline Beecham is developing the 5-HT6 antagonist, SB-271046, as a potential cognition enhancer. By December 1999, phase I trials had commenced [360354]. This drug was originally being developed primarily for the treatment of shizophrenia [284490], however, cognitive disorders, including but not limited to Alzheimer's disease, have been the main target since 1998 [394309]. SB-271046 is a potent, selective 5-HT6 antagonist with a pKi value of 8.9 [333710]. SB-258585, also known as 4-iodo-N-[4-methoxy-3-(4-methylpiperazin-1-yl)phenyl]benzenesulfonamide is an analog of SB-271046 [322488]...
January 2001: Current Opinion in Investigational Drugs
N Sugimoto, T Yashiki, T Miwa, K Hirabayashi
No abstract text is available yet for this article.
1970: Folia Psychiatrica et Neurologica Japonica
S M Cohen, M G Allen, W Pollin, Z Hrubec
No abstract text is available yet for this article.
June 1972: Archives of General Psychiatry
E Strömgren
Epidemiological studies with regard to shizophrenia encounter differences in nozological concepts, refinement of symptomatological description, etc. The WHO international pilot study of schizophrenia has succeeded in providing a reasonalby reliable tool for a unified evaluation of patients' present state. However, the combination of the present state examination with the case history will give better possibilities for a delimitation of a group of schizophrenics which is meaningful for the determination expectancy figures for schizophrenia...
1975: Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova
B B Perlman
Studies dealing with psychiatric concomitants of epilepsy and penetrating brain injury suggest that phenomena seen may be based on the side of injury. A separate, growing literature has begun to relate shizophrenia directly to problems of inter-hemispheric relation. Experimental work on animal rotation also deals with aspects of cerebral asymmetry. The chemical and anatomic systems manipulated in the animal work are the same as those postulated to be central to a biological understanding of schizophrenia. How these seemingly disparate subject matters may merge and point to a plausible animal model for the schizophrenias is the hypothesis presented in this paper...
November 1976: Medical Hypotheses
Iu A Il'inskiĭ, G Ia Lukacher, V M Cherniavskiĭ
No abstract text is available yet for this article.
March 1976: Sovetskaia Meditsina
R H Belmaker, R P Ebstein, H Dasberg, A Levy, G Sedvall, H M Van Praag
Recent reports have suggested that high doses of propranolol may be an effective treatment in schizophrenia. To determine whether such treatment has effects on cerebrospinal fluid (CSF) amine metabolites and prolactin similar to the effects of the neuroleptic drugs, we studied CSF from ten patients before and after propanolol therapy. The initial CSF sample was removed after a drug-free period and propranolol dosage was then increased over 1 week to 1000 mg daily in all ten patients. A second CSF sample was removed after 3 weeks of propranolol therapy...
June 21, 1979: Psychopharmacology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"